A phase II, randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in patients with ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2014

ABSTRACT

Background and study aims Falls are common in people with Parkinson's disease (PD). A quarter of people with PD fall at least once a month and they are twice as likely to fall on recurrent occasions compared to older people without PD. The consequences of falls are devastating and costly to the person affected, their carer and society. Falls lead to hospital admission, hip fracture, anxiety and fear of further falls and increase the likelihood of having to live in a nursing home. Apart from the motor features of PD (tremor, stiffness and slowness of movement) impairment in balance is the most common impairment that affects quality of life. Despite the high rate of falls, there are no medical treatments that have been assessed and proven to reduce the risk of falling. This project aims to discover how well rivastigmine works on correcting the difficulties people with PD have with walking. Rivastigmine is a drug that is licensed for treating memory problems, including memory problems associated with PD. How well it works in improving walking, balance and freezing has not been systematically studied and that is the reason for this study. Who can participate? We will recruit 130 men and women with PD, from 18-100 years old, who have had a fall in the past year. A small subset of 5-10 healthy people without PD will be asked to have their walking measured in a laboratory. This will enable us to check the equipment we use and devise suitable tests that people perform whilst they walk. What does the study involve? People who take part in the study will be involved for one year. You will take active or placebo (dummy) medication for the first 32 weeks. About half the people who take part will receive the active (real) medication and the other half will receive the placebo (dummy) medication. We will test your walking and balance in detail on two occasions – at the start and after 32 weeks. For the remainder of the year you will be asked to record any falls that occur in diaries at home and return these to us each month. What are the possible benefits and risks in participating? If you are in the group that receives the active medication capsules your walking unsteadiness and /or balance impairment may improve along with your attention, concentration and memory. You have a 50% chance of being able to access a potentially new and helpful drug to treat aspects of PD. You may be reassured and benefit from the frequent visits and follow up. We cannot promise the study will help you but the information we get from this study will improve the treatment of people with PD in the future. The medication can have side effects. One of the more common side effects is stomach upset (feeling sick, vomiting or having diarrhoea). More information is available about possible side effects and what happens if they occur in the Information Leaflet available from the research team. Where is the study run from? The study is run from Frenchay Hospital which is part of North Bristol NHS Trust. Some people who take part may have their Parkinson’s disease treated at other hospitals in the area. However, all the assessments in the trial will take place at Frenchay Hospital. When is the study starting and how long is it expected to run for? We aim to start recruiting people to take part towards the end of 2011. We will continue to recruit people until we reach 130 participants which is likely to take 12-18 months. Who is funding the study? The study is funded by a Parkinson's UK training fellowship award. Who is the main contact? Dr Emily Henderson, Emily.Henderson@bris.ac.uk Dr Alan Whone, Alan.Whone@btinternet.com More... »

URL

http://www.isrctn.com/ISRCTN19880883

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background and study aims\nFalls are common in people with Parkinson's disease (PD). A quarter of people with PD fall at least once a month and they are twice as likely to fall on recurrent occasions compared to older people without PD. The consequences of falls are devastating and costly to the person affected, their carer and society. Falls lead to hospital admission, hip fracture, anxiety and fear of further falls and increase the likelihood of having to live in a nursing home. Apart from the motor features of PD (tremor, stiffness and slowness of movement) impairment in balance is the most common impairment that affects quality of life. Despite the high rate of falls, there are no medical treatments that have been assessed and proven to reduce the risk of falling. \nThis project aims to discover how well rivastigmine works on correcting the difficulties people with PD have with walking.  Rivastigmine is a drug that is licensed for treating memory problems, including memory problems associated with PD.  How well it works in improving walking, balance and freezing has not been systematically studied and that is the reason for this study. \n\nWho can participate?\nWe will recruit 130 men and women with PD, from 18-100 years old, who have had a fall in the past year. A small subset of 5-10 healthy people without PD will be asked to have their walking measured in a laboratory.  This will enable us to check the equipment we use and devise suitable tests that people perform whilst they walk. \n\nWhat does the study involve? \nPeople who take part in the study will be involved for one year.  You will take active or placebo (dummy) medication for the first 32 weeks. About half the people who take part will receive the active (real) medication and the other half will receive the placebo (dummy) medication.  We will test your walking and balance in detail on two occasions \u0096 at the start and after 32 weeks.  For the remainder of the year you will be asked to record any falls that occur in diaries at home and return these to us each month.  \n\nWhat are the possible benefits and risks in participating? \nIf you are in the group that receives the active medication capsules your walking unsteadiness and /or balance impairment may improve along with your attention, concentration and memory.  You have a 50% chance of being able to access a potentially new and helpful drug to treat aspects of PD.\nYou may be reassured and benefit from the frequent visits and follow up.  We cannot promise the study will help you but the information we get from this study will improve the treatment of people with PD in the future.    \nThe medication can have side effects.  One of the more common side effects is stomach upset (feeling sick, vomiting or having diarrhoea).  More information is available about possible side effects and what happens if they occur in the Information Leaflet available from the research team.  \n\nWhere is the study run from?\nThe study is run from Frenchay Hospital which is part of North Bristol NHS Trust. Some people who take part may have their Parkinson\u0092s disease treated at other hospitals in the area.  However, all the assessments in the trial will take place at Frenchay Hospital. \n\nWhen is the study starting and how long is it expected to run for? \nWe aim to start recruiting people to take part towards the end of 2011.  We will continue to recruit people until we reach 130 participants which is likely to take 12-18 months. \n\nWho is funding the study? \nThe study is funded by a Parkinson's UK training fellowship award. \n\nWho is the main contact? \nDr Emily Henderson, Emily.Henderson@bris.ac.uk\nDr Alan Whone, Alan.Whone@btinternet.com", 
    "endDate": "2014-04-30T00:00:00Z", 
    "id": "sg:clinicaltrial.ISRCTN19880883", 
    "keywords": [
      "detail", 
      "hip fracture", 
      "Main", 
      "anxiety", 
      "Healthy People", 
      "frequent visit", 
      "leaflet", 
      "laboratory", 
      "emotion", 
      "remainder", 
      "possible benefit", 
      "high rate", 
      "nursing home", 
      "return", 
      "likelihood", 
      "unsteadiness", 
      "Parkinson's", 
      "drug", 
      "NHS Trusts", 
      "possible side effect", 
      "Fall", 
      "diarrhea", 
      "trial", 
      "gait", 
      "stiffness", 
      "Parkinson Disease", 
      "men", 
      "vomiting", 
      "active medication", 
      "small subset", 
      "life", 
      "hospital admission", 
      "slowness", 
      "woman", 
      "Parkinson\u0092s disease", 
      "patient", 
      "run", 
      "Phase II", 
      "Alan", 
      "caregiver", 
      "movement", 
      "half", 
      "benefit", 
      "start", 
      "Equipment and Supply", 
      "stomach", 
      "training fellowship", 
      "common side effect", 
      "fear", 
      "society", 
      "freezing", 
      "consequence", 
      "assessment", 
      "medication", 
      "aspect", 
      "home", 
      "occasion", 
      "Drs", 
      "medical treatment", 
      "diary", 
      "quarter", 
      "rivastigmine", 
      "memory problem", 
      "balance impairment", 
      "hospital", 
      "old people", 
      "side effect", 
      "Attention", 
      "impairment", 
      "Henderson", 
      "dummy", 
      "feature", 
      "research team", 
      "balance", 
      "risk", 
      "memory", 
      "placebo", 
      "tremor"
    ], 
    "name": "A phase II, randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in patients with Parkinson\u0092s disease who have fallen", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/ISRCTN19880883"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/isrctn_ct_data_00000.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.453145.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.5337.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.418484.5", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2377-13-188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014463811", 
          "https://doi.org/10.1186/1471-2377-13-188"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "http://www.isrctn.com/ISRCTN19880883"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN19880883'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN19880883'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN19880883'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.ISRCTN19880883'


 

This table displays all metadata directly associated to this object as RDF triples.

108 TRIPLES      16 PREDICATES      97 URIs      87 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.ISRCTN19880883 schema:about anzsrc-for:3053
2 anzsrc-for:3177
3 schema:description Background and study aims Falls are common in people with Parkinson's disease (PD). A quarter of people with PD fall at least once a month and they are twice as likely to fall on recurrent occasions compared to older people without PD. The consequences of falls are devastating and costly to the person affected, their carer and society. Falls lead to hospital admission, hip fracture, anxiety and fear of further falls and increase the likelihood of having to live in a nursing home. Apart from the motor features of PD (tremor, stiffness and slowness of movement) impairment in balance is the most common impairment that affects quality of life. Despite the high rate of falls, there are no medical treatments that have been assessed and proven to reduce the risk of falling. This project aims to discover how well rivastigmine works on correcting the difficulties people with PD have with walking. Rivastigmine is a drug that is licensed for treating memory problems, including memory problems associated with PD. How well it works in improving walking, balance and freezing has not been systematically studied and that is the reason for this study. Who can participate? We will recruit 130 men and women with PD, from 18-100 years old, who have had a fall in the past year. A small subset of 5-10 healthy people without PD will be asked to have their walking measured in a laboratory. This will enable us to check the equipment we use and devise suitable tests that people perform whilst they walk. What does the study involve? People who take part in the study will be involved for one year. You will take active or placebo (dummy) medication for the first 32 weeks. About half the people who take part will receive the active (real) medication and the other half will receive the placebo (dummy) medication. We will test your walking and balance in detail on two occasions – at the start and after 32 weeks. For the remainder of the year you will be asked to record any falls that occur in diaries at home and return these to us each month. What are the possible benefits and risks in participating? If you are in the group that receives the active medication capsules your walking unsteadiness and /or balance impairment may improve along with your attention, concentration and memory. You have a 50% chance of being able to access a potentially new and helpful drug to treat aspects of PD. You may be reassured and benefit from the frequent visits and follow up. We cannot promise the study will help you but the information we get from this study will improve the treatment of people with PD in the future. The medication can have side effects. One of the more common side effects is stomach upset (feeling sick, vomiting or having diarrhoea). More information is available about possible side effects and what happens if they occur in the Information Leaflet available from the research team. Where is the study run from? The study is run from Frenchay Hospital which is part of North Bristol NHS Trust. Some people who take part may have their Parkinson’s disease treated at other hospitals in the area. However, all the assessments in the trial will take place at Frenchay Hospital. When is the study starting and how long is it expected to run for? We aim to start recruiting people to take part towards the end of 2011. We will continue to recruit people until we reach 130 participants which is likely to take 12-18 months. Who is funding the study? The study is funded by a Parkinson's UK training fellowship award. Who is the main contact? Dr Emily Henderson, Emily.Henderson@bris.ac.uk Dr Alan Whone, Alan.Whone@btinternet.com
4 schema:endDate 2014-04-30T00:00:00Z
5 schema:keywords Alan
6 Attention
7 Drs
8 Equipment and Supply
9 Fall
10 Healthy People
11 Henderson
12 Main
13 NHS Trusts
14 Parkinson Disease
15 Parkinson's
16 Parkinson’s disease
17 Phase II
18 active medication
19 anxiety
20 aspect
21 assessment
22 balance
23 balance impairment
24 benefit
25 caregiver
26 common side effect
27 consequence
28 detail
29 diarrhea
30 diary
31 drug
32 dummy
33 emotion
34 fear
35 feature
36 freezing
37 frequent visit
38 gait
39 half
40 high rate
41 hip fracture
42 home
43 hospital
44 hospital admission
45 impairment
46 laboratory
47 leaflet
48 life
49 likelihood
50 medical treatment
51 medication
52 memory
53 memory problem
54 men
55 movement
56 nursing home
57 occasion
58 old people
59 patient
60 placebo
61 possible benefit
62 possible side effect
63 quarter
64 remainder
65 research team
66 return
67 risk
68 rivastigmine
69 run
70 side effect
71 slowness
72 small subset
73 society
74 start
75 stiffness
76 stomach
77 training fellowship
78 tremor
79 trial
80 unsteadiness
81 vomiting
82 woman
83 schema:name A phase II, randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in patients with Parkinson’s disease who have fallen
84 schema:sameAs https://app.dimensions.ai/details/clinical_trial/ISRCTN19880883
85 schema:sdDatePublished 2019-03-07T15:20
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher Nedb4d2e550604d5f9f61c88459bb6bcc
88 schema:sponsor https://www.grid.ac/institutes/grid.418484.5
89 https://www.grid.ac/institutes/grid.453145.2
90 https://www.grid.ac/institutes/grid.5337.2
91 schema:startDate 2011-12-01T00:00:00Z
92 schema:subjectOf sg:pub.10.1186/1471-2377-13-188
93 schema:url http://www.isrctn.com/ISRCTN19880883
94 sgo:license sg:explorer/license/
95 sgo:sdDataset clinical_trials
96 rdf:type schema:MedicalStudy
97 Nedb4d2e550604d5f9f61c88459bb6bcc schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
100 rdf:type schema:DefinedTerm
101 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
102 rdf:type schema:DefinedTerm
103 sg:pub.10.1186/1471-2377-13-188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014463811
104 https://doi.org/10.1186/1471-2377-13-188
105 rdf:type schema:CreativeWork
106 https://www.grid.ac/institutes/grid.418484.5 schema:Organization
107 https://www.grid.ac/institutes/grid.453145.2 schema:Organization
108 https://www.grid.ac/institutes/grid.5337.2 schema:Organization
 




Preview window. Press ESC to close (or click here)


...